CoChat
Sign Up
Cited by 19Inflammatory Biomarkers in Disease PrognosisTesticular diseases and treatmentsLung Cancer Research Studies

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy

Open access
Cursano, Maria Concetta, Kopf, Barbara, Scarpi, Emanuela, Menna, Cecilia, Casadei, Chiara, Schepisi, Giuseppe, Lolli, Cristian, Altavilla, Amelia, Gallà, Valentina, Santini, Daniele, Tonini, Giuseppe, Chovanec, Michal, Mego, Michal, De Giorgi, Ugo·2020·Frontiers in Oncology
DOI 10.3389/fonc.2020.01325PMC PMC7457022
Open this paper in CoChat — free accountOpen PDF

Abstract

High-dose chemotherapy (HDCT) has curative potential in relapsed/refractory germ cell tumors (GCT). Due to the complexity of this population and the toxicity of HDCT, we evaluated the association between blood-based systemic inflammatory indexes and the outcome of GCT patients undergoing salvage treatment with HDCT in order to define additional prognostic factors able to orient clinical decision. Baseline characteristics, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and the systemic immune-inflammation index (SII) of 62 patients undergoing HDCT for GCT were retrospectively collected. The aim is to evaluate the correlation between each inflammatory marker (NLR, PLR, and SII) and response to HDCT, overall survival (OS), and progression-free survival (PFS). Using the receiver operating curve to identify the best cutoff values, it was found that patients with GCT with NLR ≥3.3 and SII ≥844,000 had shorter PFS and inferior OS. In the multivariable analysis including inflammatory markers, the International Prognostic Factor Study Group (IPFSG) risk group, age, and previous line of treatment, NLR ≥3.3 and SII ≥844,000 were identified to be independently associated with shorter PFS and OS. Moreover, NLR, PLR, and SII significantly correlate with overall response to HDCT. Associating IPFSG prognostic score to inflammatory markers at baseline of HDCT may improve prognostic information and could help physicians to make more personalized treatment decisions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2020.01325

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Various studies reported significant differences between NLR, LMR, and SII in early and advanced stage GCTs.

    “Various studies reported that there were significant differences between neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation index (SII), in early and advanced stage GCTs [31,32,33,34,35].”

    From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [35]

    The Discussion says NLR could help predict TNM stage in testicular GCT and reports studies linking SII to prognosis in metastatic GCT. It does not report significant differences in NLR, LMR, and SII between early- and advanced-stage GCTs. The Methods and Results assess NLR, PLR, and SII in patients receiving salvage high-dose chemotherapy, not LMR or an early-versus-advanced-stage comparison. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. Lorch, 2017, How we treat germ cell cancers, Cancer., 123, 2190, 10.1002/cncr.30751 · DOI
  2. Fizazi, 2008, Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study, Ann Oncol., 19, 259, 10.1093/annonc/mdm472 · DOI
  3. Loehrer, 1998, Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor, J Clin Oncol., 16, 2500, 10.1200/JCO.1998.16.7.2500 · DOI
  4. Kondagunta, 2005, Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors, J Clin Oncol., 23, 6549, 10.1200/JCO.2005.19.638 · DOI
  5. Bokemeyer, 1999, Treatment of patients with cisplatin-refractory testicular germ-cell cancer, Int J Cancer., 83, 848, 10.1002/(sici)1097-0215(19991210)83:6<848::aid-ijc29>3.0.co;2-# · DOI
  6. De Giorgi, 2006, Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor, Eur Urol., 50, 1032, 10.1016/j.eururo.2006.05.011 · DOI · Paper page
  7. De Giorgi, 2005, Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience, Ann Oncol., 16, 146, 10.1093/annonc/mdi017 · DOI · Paper page
  8. Feldman, 2016, Brain metastases in patients with germ cell tumors: prognostic factors and treatment options–an analysis from the global germ cell cancer group, J Clin Oncol., 34, 345, 10.1200/JCO.2015.62.7000 · DOI
  9. Lorch, 2010, Prognostic factor in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first line chemotherapy, J Clin Oncol., 28, 4906, 10.1200/JCO.2009.26.8128 · DOI
  10. Rossi, 2015, High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer, Ann Surg Oncol., 22, 1377, 10.1245/s10434-014-4097-4 · DOI
  11. Lolli, 2016, Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib, Oncotarget., 7, 54564, 10.18632/oncotarget.10515 · DOI
  12. Zheng, 2017, Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review, Cell Physiol Biochem., 44, 967, 10.1159/000485396 · DOI
  13. Passardi, 2016, Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer, Oncotarget., 7, 33210, 10.18632/oncotarget.8901 · DOI
  14. Lolli, 2016, Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone, Front Pharmacol., 7, 376, 10.3389/fphar.2016.00376 · DOI
  15. Feldman, 2010, TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis, J Clin Oncol., 28, 1706, 10.1200/JCO.2009.25.1561 · DOI
  16. De Giorgi, 2012, Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer, Clin Breast Cancer., 12, 264, 10.1016/j.clbc.2012.04.004 · DOI
  17. Mantovani, 2008, Cancer-related inflammation, Nature., 454, 436, 10.1038/nature07205 · DOI · Paper page
  18. Schumacher, 2013, Platelet-derived nucleotides promote tumorcell transendothelial migration and metastasis via P2Y2 receptor, Cancer Cell., 24, 130, 10.1016/j.ccr.2013.05.008 · DOI
  19. Labelle, 2011, Direct signaling between platelets and cancer cells induces epithelial-mesenchymallike transition and promote metastasis, Cancer Cell., 20, 576, 10.1016/j.ccr.2011.09.009 · DOI · Paper page
  20. Minami, 2015, Identification of programmed death ligand 1-derived peptides capable of inducing cancerreactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma, J Immunother., 38, 285, 10.1097/CJI.0000000000000090 · DOI
  21. Jankovich, 2017, Neutrophil-to-lymphocyte ratio as a predictor of preoperative tumor staging in testicular germ cell tumors, Bratisl Med J., 118, 510, 10.4149/BLL_2017_098 · DOI
  22. Bolat, 2017, Predictive value of preoperative neutrophil-to-lymphocyte ratio on the prognosis of germ cell testicular tumors, Turk J Urol., 43, 55, 10.5152/tud.2016.38924 · DOI
  23. Chovanec, 2018, Systemic immune-inflammation index in germ-cell tumours, Br J Cancer., 118, 831, 10.1038/bjc.2017.460 · DOI · Paper page
  24. Fankhauser, 2018, Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy, Br J Cancer., 118, 825, 10.1038/bjc.2017.467 · DOI · Paper page
  25. Adra, 2017, High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience, J Clin Oncol., 35, 1096, 10.1200/JCO.2016.69.5395 · DOI
  26. Hanna, 2014, Testicular cancer—discoveries and updates, N Engl J Med., 371, 2005, 10.1056/NEJMra1407550 · DOI

Cited by

Sorted by citations

Metadata

Authors
Cursano, M. C., Kopf, B., Scarpi, E., Menna, C., Casadei, C., Schepisi, G., Lolli, C., Altavilla, A., Gallà, V., Santini, D., Tonini, G., Chovanec, M., Mego, M., & De Giorgi, U.
Affiliations
  • Sapienza University of Rome (IT)
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
  • Comenius University Bratislava (SK)
Corresponding author
Cursano, Maria Concetta
ORCID
Venue
Frontiers in Oncology
Publisher
Frontiers Media SA
Published
2020-08-14
Volume
10
Pages
1325-1325
ISSN
2234-943X (ISSN-L)
DOI
10.3389/fonc.2020.01325
PMC
PMC7457022
OpenAlex
W3039797982
Cited by
19
References
2
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 3
FWCI
1.17
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • AIRUS (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Surgery › Testicular diseases and treatments
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
germ cell tumors, high-dose chemotherapy, systemic inflammatory index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, prognostic factors, salvage therapy, overall survival, progression-free survival, treatment response

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review